{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:15:56Z","timestamp":1788336956577,"version":"build-2803163510"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,2,21]]},"abstract":"<jats:p>\n            Delafloxacin is a novel fluoroquinolone with activity against Gram-positive, Gram-negative, and atypical pathogens, including fluoroquinolone-nonsusceptible methicillin-resistant\n            <jats:named-content content-type=\"genus-species\">Staphylococcus aureus<\/jats:named-content>\n            (MRSA). The microbiological results of a phase 3 clinical trial in adults with community-acquired pneumonia (CAP) comparing delafloxacin (300\u2009mg intravenously [i.v.] with the option to switch to 450\u2009mg orally every 12 h) to moxifloxacin (400\u2009mg i.v.\n          <\/jats:p>","DOI":"10.1128\/aac.01949-19","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T11:29:12Z","timestamp":1576150152000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":30,"title":["Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial"],"prefix":"10.1128","volume":"64","author":[{"given":"Sandra","family":"McCurdy","sequence":"first","affiliation":[{"name":"Melinta Therapeutics, Morristown, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Keedy","sequence":"additional","affiliation":[{"name":"Melinta Therapeutics, Morristown, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Melinta Therapeutics, Morristown, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Nenninger","sequence":"additional","affiliation":[{"name":"Melinta Therapeutics, Morristown, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Sheets","sequence":"additional","affiliation":[{"name":"Melinta Therapeutics, Morristown, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Quintas","sequence":"additional","affiliation":[{"name":"Melinta Therapeutics, Morristown, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Cammarata","sequence":"additional","affiliation":[{"name":"Melinta Therapeutics, Morristown, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.09.022"},{"key":"e_1_3_3_3_2","volume-title":"HCUP statistical brief #168. Costs for hospital stays in the United States, 2011","author":"Pfuntner A","year":"2013","unstructured":"Pfuntner A, Wier LM, Steiner C. 2013. HCUP statistical brief #168. Costs for hospital stays in the United States, 2011. Agency for Healthcare Research and Quality, Rockville, MD. http:\/\/www.hcup-us.ahrq.gov\/reports\/statbriefs\/sb168-Hospital-Costs-United-States-2011.pdf."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500245"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw300"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00772-17"},{"key":"e_1_3_3_7_2","volume-title":"Baxdela prescribing information","author":"Melinta Therapeutics","year":"2017","unstructured":"Melinta Therapeutics. 2017. Baxdela prescribing information. Melinta Therapeutics, Lincolnshire, IL. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208610s007,208611s006lbl.pdf."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz090"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800201"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.8241"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2016.0186"},{"key":"e_1_3_3_12_2","volume-title":"Guidance for industry. Community-acquired bacterial pneumonia: developing drugs for treatment. Draft guidance","author":"Food and Drug Administration","year":"2014","unstructured":"Food and Drug Administration. 2014. Guidance for industry. Community-acquired bacterial pneumonia: developing drugs for treatment. Draft guidance. Food and Drug Administration, Rockville, MD."},{"key":"e_1_3_3_13_2","volume-title":"Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections","author":"European Medicines Agency, Committee for Human Medicinal Products","year":"2013","unstructured":"European Medicines Agency, Committee for Human Medicinal Products. 2013. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. EMA\/CHMP\/351889\/2013. European Medicines Agency, London, United Kingdom. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2013\/11\/WC500153953.pdf."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00017-7"},{"key":"e_1_3_3_15_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard, 11th ed. CLSI document M07-A11. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"11"},{"key":"e_1_3_3_16_2","volume-title":"Performance standards for antimicrobial susceptibility testing; twenty-seventh informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2017","unstructured":"Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing; twenty-seventh informational supplement. CLSI document M100-S27. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_17_2","volume-title":"Development of in vitro susceptibility testing criteria and quality control parameters: approved guideline","author":"Clinical and Laboratory Standards Institute","year":"2016","unstructured":"Clinical and Laboratory Standards Institute. 2016. Development of in vitro susceptibility testing criteria and quality control parameters: approved guideline, 3rd ed. CLSI document M45. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"3"},{"key":"e_1_3_3_18_2","volume-title":"Performance standards for antimicrobial susceptibility testing; twenty-eighth informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing; twenty-eighth informational supplement. CLSI document M100-S28. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_19_2","volume-title":"Cumitech 34, Laboratory diagnosis of mycoplasmal infections","author":"Waites K","year":"2001","unstructured":"Waites K, Bebear C, Robertson D, Talkington DF, Kenny GE. 2001. Cumitech 34, Laboratory diagnosis of mycoplasmal infections. Coordinating ed, Nolde FS. ASM Press, Washington, DC."},{"key":"e_1_3_3_20_2","volume-title":"Methods for antimicrobial susceptibility testing for human mycoplasmas; approved guideline","author":"Clinical and Laboratory Standards Institute","year":"2011","unstructured":"Clinical and Laboratory Standards Institute. 2011. Methods for antimicrobial susceptibility testing for human mycoplasmas; approved guideline. CLSI document M43-A. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_21_2","volume-title":"Performance standards for antimicrobial susceptibility testing; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; approved standard, 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"9"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/23.1.37"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-0258"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/femsle\/fnx173"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02498-06"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01949-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01949-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:47:53Z","timestamp":1645480073000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01949-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,2,21]]}},"alternative-id":["10.1128\/AAC.01949-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.01949-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]},"assertion":[{"value":"2019-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01949-19"}}